Prostate Cancer Metastatic Clinical Trials

26 recruiting

Prostate Cancer Metastatic Trials at a Glance

38 actively recruiting trials for prostate cancer metastatic are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Paris, Boston, and Chicago. Lead sponsors running prostate cancer metastatic studies include UNICANCER, University of Chicago, and Centre Henri Becquerel.

Browse prostate cancer metastatic trials by phase

Treatments under study

About Prostate Cancer Metastatic Clinical Trials

Looking for clinical trials for Prostate Cancer Metastatic? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Cancer Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Cancer Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 3

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Prostate Cancer Metastatic
UNICANCER300 enrolled95 locationsNCT04916613
Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Prostate CancerAdvanced Prostate CancerProstate Cancer Metastatic Disease+1 more
Maastricht Radiation Oncology600 enrolled3 locationsNCT07004582
Recruiting
Not Applicable

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Prostate CancerProstate Cancer Metastatic
University of California, San Francisco80 enrolled1 locationNCT06171139
Recruiting

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

Prostate CancerProstate Cancer MetastaticProstate Cancer (Adenocarcinoma)+3 more
Société Algérienne de Formation et Recherche en Oncologie2,000 enrolled24 locationsNCT07484971
Recruiting
Phase 3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Phase 2

Castrate Resistant Prostate Cancer Enhertu Therapy

Prostate CancerProstate Cancer MetastaticCRPC
Washington D.C. Veterans Affairs Medical Center60 enrolled1 locationNCT06610825
Recruiting
Phase 2

Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

Prostate Cancer Metastatic
Centre hospitalier de l'Université de Montréal (CHUM)80 enrolled1 locationNCT05457699
Recruiting
Phase 2

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Prostate Cancer Metastatic Disease
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine192 enrolled1 locationNCT06832774
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+12 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting
Phase 2

Using FAPI PET/MRI to Evaluate Prostate Cancer

Prostate CancersProstate Cancer Metastatic Disease
University of Wisconsin, Madison30 enrolled1 locationNCT06675357
Recruiting
Phase 2

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Prostate Cancer SurgeryProstate Cancer Metastatic Disease
Clinton Bahler22 enrolled3 locationsNCT06849544
Recruiting

PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

Prostate Cancer MetastaticPSMA Positive Tumors or Tumor Tissues
IRCCS Azienda Ospedaliero-Universitaria di Bologna1,300 enrolled4 locationsNCT07089550
Recruiting
Not Applicable

PSMA PET for Surveillance After Focal Therapy

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic DiseaseProstate Cancer (Diagnosis)
University of Chicago62 enrolled1 locationNCT07115914
Recruiting
Not Applicable

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

Prostate Cancer MetastaticRadiation Therapy
Karin Soderkvist118 enrolled7 locationsNCT04983095
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Not Applicable

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Prostate CancerProstate Cancer MetastaticAndrogen Deprivation Therapy
Dana-Farber Cancer Institute62 enrolled1 locationNCT05327465
Recruiting
Not Applicable

Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

Prostate Cancer Metastatic
Centre Henri Becquerel60 enrolled1 locationNCT06450548
Recruiting

Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer

Prostate Cancer Metastatic Disease
University Hospital, Grenoble130 enrolled1 locationNCT06828263
Recruiting
Not Applicable

Role of Race in Nutritional Approach in Men on ADT

Prostate Cancer Metastatic Disease
University of California, Los Angeles70 enrolled2 locationsNCT06682390
Recruiting
Phase 2

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Prostate CancerProstate Cancer Metastatic
Martha Mims130 enrolled3 locationsNCT03833921